IPO News | Taili Biotech's Hong Kong Stock IPO Prospectus Expires

Zhitongcaijing · 1d ago

The Zhitong Finance App learned that the Hong Kong Stock Prospectus submitted by Tyligand Bioscience Ltd. (abbreviation: Tyligand Bioscience Ltd.) on January 29, 2026 expired for 6 months and expired on July 29, 2026, and CITIC Securities was its sole sponsor.

Tairi.png

According to the previous prospectus, Taili Biotech is a clinical-stage biopharmaceutical company founded in 2017, focusing on the discovery and development of innovative oncology therapies. The company's drug portfolio includes four drug candidates, including a core product TSN1611 in phase 2 clinical trials, an additional clinical-stage candidate TSN222, and two pre-clinical drug candidates TSNA1789 and TSNA3339. The company's core drug candidate, TSN1611, is a highly selective oral KRAS G12D inhibitor. As one of the most common carcinogenic driver mutations, KRAS G12D has historically been a difficult treatment. TSN1611 is currently undergoing phase 2 clinical trials in the US and China, and plans to advance key registered clinical trials for the treatment of non-small cell lung cancer (NSCLC) in China.